Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Mujais

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Hypertension (Dallas, Tex. : 1979)|September 1, 1983
Responses of the stenosed and contralateral kidneys to [Sar1, Thr8] AII in human renovascular hypertensionS C Textor, A Novick, S K Mujais, et al.
JAMA|January 21, 1983
Predictive value of angiotensin II antagonists in renovascular hypertensionF M Fouad, R W Gifford, S Fighali, et al.
Clinical Pharmacology and Therapeutics|November 15, 2012
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT studyM Malik, E M van Gelderen, J H Lee, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Hypertension (Dallas, Tex. : 1979)|September 1, 1983
Responses of the stenosed and contralateral kidneys to [Sar1, Thr8] AII in human renovascular hypertensionS C Textor, A Novick, S K Mujais, et al.
JAMA|January 21, 1983
Predictive value of angiotensin II antagonists in renovascular hypertensionF M Fouad, R W Gifford, S Fighali, et al.
Clinical Pharmacology and Therapeutics|November 15, 2012
Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT studyM Malik, E M van Gelderen, J H Lee, et al.
Pageof 8